{"nctId":"NCT00369317","briefTitle":"Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes","startDateStruct":{"date":"2007-03"},"conditions":["Childhood Acute Basophilic Leukemia","Childhood Acute Eosinophilic Leukemia","Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myelomonocytic Leukemia (M4)","Childhood Myelodysplastic Syndromes","de Novo Myelodysplastic Syndromes","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndromes","Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies"],"count":205,"armGroups":[{"label":"Treatment (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: daunorubicin hydrochloride","Drug: cytarabine","Drug: thioguanine","Drug: etoposide","Other: laboratory biomarker analysis"]}],"interventions":[{"name":"asparaginase","otherNames":["ASNase","Colaspase","Crasnitin","Elspar","L-ASP"]},{"name":"daunorubicin hydrochloride","otherNames":["Cerubidin","Cerubidine","daunomycin hydrochloride","daunorubicin","RP-13057"]},{"name":"cytarabine","otherNames":["ARA-C","arabinofuranosylcytosine","arabinosylcytosine","Cytosar-U","cytosine arabinoside"]},{"name":"thioguanine","otherNames":["6-TG"]},{"name":"etoposide","otherNames":["EPEG","VP-16","VP-16-213"]},{"name":"laboratory biomarker analysis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis DS or DS mosaicism by karyotype or chromosomal analysis\n* Diagnosis of myelodysplastic syndromes (MDS) with \\< 30% blasts or acute myeloid leukemia (AML)\n\n  * Newly diagnosed disease\n* Patients with a history of transient myeloproliferative disorder (TMD) are eligible provided the patient is diagnosed with AML or MDS at \\> 90 days of age AND meets either of the following criteria:\n\n  * At least 30% blasts in the bone marrow regardless of time since resolution of TMD\n  * More than 8 weeks since resolution of TMD with ≥ 5% blasts in the bone marrow\n* Immunophenotype required for study entry\n* No promyelocytic leukemia\n* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* AST or ALT \\< 2.5 times ULN\n* Creatinine adjusted according to age as follows:\n\n  * No greater than 0.4 mg/dL (≤ 5 months)\n  * No greater than 0.5 mg/dL (6 months -11 months)\n  * No greater than 0.6 mg/dL (1 year-23 months)\n  * No greater than 0.8 mg/dL (2 years-5 years)\n  * No greater than 1.0 mg/dL (6 years-9 years)\n  * No greater than 1.2 mg/dL (10 years-12 years)\n  * No greater than 1.4 mg/dL (13 years and over \\[female\\])\n  * No greater than 1.5 mg/dL (13 years to 15 years \\[male\\])\n  * No greater than 1.7 mg/dL (16 years and over \\[male\\])\n* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min\n* No evidence of dyspnea at rest\n* No exercise intolerance\n* Pulse oximetry \\> 94%\n* No prior chemotherapy, radiotherapy, or any antileukemic therapy\n\n  * Intrathecal cytarabine therapy given at diagnosis allowed\n* Prior therapy for TMD allowed","healthyVolunteers":false,"sex":"ALL","maximumAge":"4 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival (EFS) at 3 Years","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS) at 3 Years","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Remission Rate","description":"Proportion of participants with a remission after four courses of Induction therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.984615","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Experiencing Grade 3 or 4 Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","description":"Proportion of participants with at least one grade 3 or higher adverse event during therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.911765","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of Leukemia Phenotype of DS Patients < 4 Years of Age at Diagnosis by Flow Cytometry","description":"Proportion of participants having megakaryoblastic subtype (AMkL) phenotype among patients with phenotype data available.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45122","spread":null}]}]}]},{"type":"SECONDARY","title":"Prevalence of of GATA1 Mutations of DS Patients < 4 Years of Age at Diagnosis","description":"Proportion of participants having GATA1 mutation among patients with phenotype data available.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.891304","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportions of Patients in Morphologic Remission With Positive MRD by Flow Cytometry","description":"Proportion of participants in complete remission by morphology and with positive MRD by flow cytometry among patients having evaluable remission and MRD assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0935254","spread":null}]}]}]},{"type":"SECONDARY","title":"Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program","description":"Mean and standard deviation of peak plasma concentration. Specimen draws were performed only with dose 1, day 1 of induction II of AraC. First sample drawn pre-infusion, then drawn 30 mins prior to the end of the infusion, and then drawn for 6 time periods post infusion up to 8 hours post infusion (and before the 2nd dose of AraC). Results are based from these multiple time points on Day 1 of Induction II only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.69931","spread":"18.545798"}]}]}]},{"type":"SECONDARY","title":"Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program","description":"Mean and standard deviation of area under the concentration time curve. Specimen draws were performed only with dose 1, day 1 of induction II of AraC. First sample drawn pre-infusion, then drawn 30 mins prior to the end of the infusion, and then drawn for 6 time periods post infusion up to 8 hours post infusion (and before the 2nd dose of AraC). Results are based from these multiple time points on Day 1 of Induction II only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1337.279","spread":"1172.20853"}]}]}]},{"type":"SECONDARY","title":"Cytarabine Drug Sensitivity by R-Strip (MicroMath) Curve Fitting Program","description":"Mean and standard deviation of half-life of elimination. Specimen draws were performed only with dose 1, day 1 of induction II of AraC. First sample drawn pre-infusion, then drawn 30 mins prior to the end of the infusion, and then drawn for 6 time periods post infusion up to 8 hours post infusion (and before the 2nd dose of AraC). Results are based from these multiple time points on Day 1 of Induction II only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306.156034","spread":"307.042662"}]}]}]},{"type":"SECONDARY","title":"Gene Expression Profiles by Microarrays","description":"A hierarchical clustering algorithm is used to assemble the genes into a dendrogram or tree structure with branches containing genes with similar patterns of expression. This ordered representation can be graphically displayed with colors that reflect the qualitative and quantitative relationships of the expressed genes.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":204},"commonTop":["Infections and infestations - Other","Febrile neutropenia","Anorexia","Alanine aminotransferase increased","Catheter related infection"]}}}